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Abstract 
Mitochondria are subcellular organelles critical for meeting the bioenergetic and 
biosynthetic needs of the cell. Mitochondrial function relies on genes and RNA 
species encoded both in the nucleus and mitochondria, as well as their coordinated 
translation, import and respiratory complex assembly. Here we describe the 
characterization of exonuclease domain like 2 (EXD2), a nuclear encoded gene that 
we show is targeted to the mitochondria and prevents the aberrant association of 
mRNAs with the mitochondrial ribosome. The loss of EXD2 resulted in defective 
mitochondrial translation, impaired respiration, reduced ATP production, increased 
reactive oxygen species and widespread metabolic abnormalities. Depletion of 
EXD2/CG6744 in D.melanogaster caused developmental delays and premature 
female germline stem cell attrition, reduced fecundity and a dramatic extension of 
lifespan that could be reversed with an anti-oxidant diet. Our results define a 
conserved role for EXD2 in mitochondrial translation that influences development and 
aging. 
Introduction  
Mitochondria maintain a circular 16.6 kb DNA genome (mtDNA) encoding 2 rRNAs, 
22 tRNAs and 13 open reading frames for electron transport chain (ETC) complex 
subunits and are the major source of ATP and the site of oxidative phosphorylation 
(OXPHOS) and the tricarboxylic acid (TCA) cycle that are essential for cellular 
respiration. In addition, mitochondria facilitate many metabolic reactions required for 
macromolecular synthesis, including production of lipids, dNTPs, heme, iron-sulfur 
clusters and amino acids1.   
The five complexes of the OXPHOS machinery carry out redox reactions from NADH 
and succinate to drive the majority of cellular ATP production through ATP synthase1. 
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While most OXPHOS proteins are encoded in the nucleus, key components of all 
complexes, except Complex II (CII), are encoded by the mtDNA. The function and 
maintenance of the OXPHOS machinery is dependent on mtDNA integrity, 
transcription, precursor RNA processing, assembly of mitochondrial specific 
ribosomes and translation, the coordinated movement of nuclear encoded proteins 
into the mitochondria, and the ordered assembly and membrane insertion of mature 
OXPHOS complexes that is thought to take place in close proximity to the mtDNA 
and mitochondrial inner membrane2. Deficiencies in assembly or function of the 
OXPHOS machinery underlies many severe human diseases3. Paradoxically, some 
OXPHOS defects extend lifespan in both worms and flies, in some cases in a 
manner dependent on increased reactive oxygen species (ROS) production4-6 that is 
classically associated with premature ageing1.  
The nuclear encoded Exonuclease 3’-5’ domain containing 2 (EXD2) has previously 
been implicated in DNA repair through a role in DNA end-resection7-10. Here we 
report that EXD2 is a mitochondrial ribonuclease that is required for mitoribosome 
integrity and efficient mitochondrial translation. EXD2 depletion led to widespread 
metabolic defects, decreased respiration and increased ROS. At the organismal level, 
EXD2/CG6744 deficiency in D.melanogaster resulted in developmental delays, 
premature female germ stem cell attrition and a dramatically extended lifespan. 
Collectively, our results define a critical role for EXD2 in mitochondrial homeostasis.  
EXD2 is a mitochondrial protein 
EXD2 encodes a 3’-5’ exonuclease (EXO) domain similar to WRN, mutated in 
Werner’s Syndrome progeria (Supplementary Fig. 1a)11. Additionally, it has a highly 
conserved C-terminal HNH endonuclease-like domain, characterized by tandem 
CXXC motifs (Supplementary Fig. 1b-d). As previous reports suggested a role in 
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DNA repair7-9, we examined EXD2 localization and found that EXD2 was 
predominantly cytoplasmic, regardless of treatment with Camptothecin (CPT) to 
induce DNA damage, and overlapped substantially with mitochondrial TOM20 (Fig. 
1a). Comparative sequence analysis identified a putative, N-terminal mitochondrial 
targeting sequence (MTS) conserved in most EXD2 homologues identified 
(Supplementary Fig. 1e). Overexpression of a GFP tagged EXD2 (EXD2-GFP) or its 
MTS fused to GFP (MTS-GFP; aa 1-61) resulted in mitochondrial GFP signal, while 
the ∆MTS-GFP (aa 1-61 deleted) protein was diffusely nucleo-cytoplasmic and 
destabilized (Fig. 1b,c). Subcellular fractionation for endogenous EXD2 (Fig. 1d) and 
transmission electron microscopy (TEM) for stably expressed EXD2-Strep-
FLAG(SF)-WT confirmed primarily mitochondrial localization (Fig. 1e and 
Supplementary Fig. 1f,g). In contrast to outer membrane (OM) proteins TOM20 or 
VDAC, that are accessible to proteinase-K (PK)-mediated digestion, EXD2 was 
resistant, similar to the inner membrane (IM) ATP5A subunit of ATP synthase (Fig. 
1f). In addition, while treatment with carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (FCCP) liberated TOM20 from the OM, EXD2 
remained relatively resistant, similar to ETC components that localize to the IM or 
matrix (Supplementary Fig. 1h). Together, these results indicate that EXD2 is an 
intra-mitochondrial protein targeted by an N-terminal MTS.  
EXD2 influences cellular metabolism  
As mitochondria play a key role in metabolism, we examined the impact of EXD2 
deficiency using complementary metabolomics approaches12, 13. EXD2 depletion (Fig. 
2a,b) led to alterations in many metabolites, including those of the TCA cycle, 
antioxidants and glycolysis (Fig. 2c). Using the NMR based PEPA technique, we 
followed 13C isotope incorporation from glucose or glutamine that are key precursors 
to many metabolites of central carbon metabolism13, 14. Pathway enrichment analysis 
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revealed significant alterations in several metabolite classes, including the 
glutathione cycle, amino acid and sugar metabolism, the pentose phosphate pathway 
(PPP) and the TCA cycle (Fig. 2d). Moreover, we observed marked defects in 
incorporation of glucose-derived carbon into many metabolites, while glutamine was 
relatively unaffected (Fig. 2e, 2f). These data indicated that EXD2 was required for 
glucose oxidation through the TCA cycle and glutathione synthesis, suggesting 
EXD2-deficient cells may have alterations in ROS or antioxidant capacity and rely on 
glutamine for the generation of key metabolites. 
EXD2 prevents ROS and is required for OXPHOS activity and ATP production 
To understand these effects, we generated EXD2 knockout (KO) cell lines using 
CRISPR/CAS9 and complemented them with SF-tagged EXD2 (EXD2-SF-WT) or 
mutants in the EXO domain (NUC) or the HNH-like domain (C1 and C2) 
(Supplementary Fig. 1a,c and 2a)15. EXD2-deficient cells had reduced glutathione 
levels (Fig. 3a), consistent with metabolomics data (Fig. 2), and increased levels of 
ROS (Fig. 3b). Expression of EXD2-SF-WT or treatment with the anti-oxidant N-
acetylcysteine (NAC), but not the EXD2-SF-NUC and C2 mutants, rescued ROS 
levels to that of WT (Fig. 3b). EXD2-deficient cells also exhibited reduced levels of 
mtDNA (Fig. 3c and Supplementary Fig. 2c,d), a phenotype associated with 
increased ROS and defective respiration16. MtDNA reduction was independent of 
clear changes in mitochondrial mass (Fig. 3d,e and Supplementary Fig. 2e) or 
mtDNA replication (Supplementary Fig. 2f) and could be rescued with expression of 
EXD2-SF-WT and partially with NAC treatment (Fig. 3c and Supplementary Fig. 2d).  
Growth of EXD2-deficient cell lines was indistinguishable from wild type (WT) 
parental U2OS cells in rich medium containing glucose and glutamine (Fig. 3f). 
However, we observed impaired growth of EXD2-KO1 cells in media lacking 
	 6	
glutamine (Fig. 3g and Supplementary Fig. 2g) that was restored by EXD2-SF-WT, 
but not EXD2-SF-NUC or C2 mutants (Fig. 3g). In contrast, NAC did not rescue, 
indicating that growth defects were not secondary to increased ROS production or 
sensitivity to hyperoxic culture conditions (Fig. 3h,i).  
Mitochondrial ROS originates predominantly from CI and CIII of the ETC17, so we 
addressed ETC function by measuring oxygen consumption rates (OCR) in both 
U2OS and MDA-MB-231 cells. Compared to parental or EXD2-SF-WT 
complemented cells, EXD2-KO1 cells exhibited reduced OCR and ATP-linked 
respiration that could not be efficiently rescued by EXD2 mutants (Fig. 3j and 
Supplementary Fig. 2h). In addition, extracellular acidification rates (ECAR) were 
elevated in EXD2-KO or mutant cells, indicative of increased aerobic glycolysis and 
lactate production that can accompany defective OXPHOS (Fig. 3k and 
Supplementary Fig. 2i)18. NAC partially rescued overall OCRs but mitochondrial ATP-
linked respiration remained impaired, suggesting reduced OXPHOS capacity could 
be one of the primary defects leading to increased ROS (Fig. 3l and Supplementary 
Fig. 2j).  
Metabolomics data indicated that reduced OCR could reflect impaired glucose usage 
in EXD2-deficient cells (Fig. 2e,f). We tested this using specific media and observed 
an increase in OCR following glucose addition that was absent in cells lacking 
functional EXD2 (Fig. 3m). To more directly confirm a role for EXD2 in ATP 
production, we analyzed ATP levels using multiple methods and observed that 
EXD2-KO1 cells had reduced levels of ATP that were rescued by EXD2-SF-WT 
expression (Fig. 3n and Supplementary Fig. 2k,l). Moreover, these defects were not 
rescued by NAC (Fig. 3n and Supplementary Fig. 2k). We therefore concluded that 
EXD2 deficiency results in impaired mitochondrial ATP production, ROS 
accumulation, reduced mtDNA levels and glutamine-dependent cell growth. 
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EXD2 associates with CI and the Mitoribosome 
To determine how EXD2 influenced metabolism, we used BioID mass spectrometry 
(BioID-MS) to identify proximity interactors19. EXD2-WT and EXD2-C2 fused to a 
FLAG-tagged BirA* biotin ligase were overexpressed in the presence of biotin in 
human AD293 cells. While BirA* expression resulted in staining throughout the cell, 
streptavidin signal was only detected in the cytoplasm of biotin-supplemented cells 
expressing EXD2-WT-BirA* or EXD2-C2-BirA* and this co-localized extensively with 
TOM20 (Fig. 4a). BioID-MS revealed an EXD2 proximity interactome composed 
almost entirely of mitochondrial proteins (Fig. 4b and Supplementary Table 2) and 
highly enriched for components of CI and the small 28S subunit of the mitoribosome 
(Fig. 4c). This included almost all of the matrix exposed CI subunits20, more than 10 
subunits of the 28S mitoribosome, proteins involved in RNA processing or 
translation/assembly (ex. GRSF1, TACO1, ACAD9, LETM1), as well as enzymes 
implicated OXPHOS substrate generation (ex. MDH2, GLS) (Fig. 4c). Most 
interactions were also observed with EXD2-C2 that fails to complement phenotypes 
of EXD2-KO1 cells. However, the representation of 28S components was specifically 
reduced compared to EXD2-WT (Fig. 4c and Supplementary Table 2), suggesting 
the HNH-like domain influenced the frequency or affinity of this subset of interactors.  
An interaction with the CI subunit NDUFA9 was observed in IP-westerns and EXD2-
KO1 cells showed a minor reduction in CI levels, as well as CI and CIII 
supercomplexes, and to a lesser extent, CV (ATP synthase), and CI dependent OCR 
was reduced (Supplementary Fig. 3a-d). As EXD2 did not appear to be present in 
fully assembled CI (Supplementary Fig. 3b), we analyzed the mitoribosome 
components and readily observed an interaction with DAP3 (28S subunit) that was 
impaired by the EXD2-SF-C2 mutant (Fig. 4d). In contrast, we did not see an 
interaction with the large mitoribosome (39S) subunit MRPL3 or VDAC, an outer 
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mitochondrial membrane protein in IP-westerns (Fig. 4d). The mitoribosome 
association was further validated by confocal microscopy, where we observed 
extensive colocalization of endogenous EXD2 and MRPL12 (Fig. 4e). This further 
established the predominant mitochondrial localization of EXD2 and suggested that 
its primary functions could be linked to the OXPHOS machinery and the 
mitoribosome. 
EXD2 prevents mitoribosomal mRNA accumulation and facilitates translation 
We therefore examined mitoribosome integrity using sucrose gradient fractionation. 
EXD2 co-fractionated with the 28S and fully assembled 55S mitoribosome, but not 
with the free 39S subunit (Fig. 5a, top panels). As early 28S association of EXD2 
suggested a potential role in or during assembly, we analyzed ribosome integrity in 
EXD2-KO1 cells or those expressing EXD2-SF-C2. In either case, we observed a 
clear shift of the 28S DAP3 subunit into higher molecular weight complexes 
overlapping with 39S fractions (Fig. 5a, middle and bottom panels). Analysis of RNA 
revealed increased 12S rRNA and mtDNA encoded mRNAs in the aberrant fractions, 
suggesting premature mt-mRNA association with the 28S could yield the larger, 
aberrant complexes (Fig. 5b, compare top to middle and bottom panels). Consistent 
with this possibility, the profiles of RNAseA treated fractions were similar regardless 
of EXD2 status (Supplementary Fig. 4a). The EXD2-C2 mutant protein did not visibly 
co-fractionate with the free 28S subunits, consistent with the HNH-like domain 
promoting the 28S association (Fig. 5a, bottom panel).  
The appearance of aberrant 28S subunits suggested that mitochondrial translation 
could be impaired, so we analyzed this using metabolic pulse labeling21. A strong 
reduction in global mitochondrial translation rates was observed in U2OS and RPE1 
cells lacking EXD2 (Fig. 5c-5f and Supplementary Fig. 4b-e) that was complemented 
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by EXD2-SF-WT, but not by EXD2-SF-NUC or C2 mutants. Further, NAC did not 
influence the phenotype (Fig. 5f), suggesting it was likely a direct result of EXD2 loss. 
Together these data indicate that EXD2 prevents inappropriate mRNA association 
with mitoribosomes and facilitates efficient mitochondrial translation that requires 
both its EXO and HNH-like domains. 
EXD2 is a ribonuclease that preferentially binds ssRNA 
As EXD2 loss appeared to influence mRNA association with mitoribosomes, we 
considered that it may function as an RNAse. We examined the activity and 
specificity of bacterially purified EXD2, as well as WRN exonuclease domain (WRN-
Exo) for comparison. The EXD2 MTS (aa 1-61) was removed for solubility, the EXD2-
NUC mutant made to control for contaminating nucleases, and the EXD2-C2 mutant, 
that failed to complement EXD2-KO1 cells, was also generated (Fig. 6a and 
Supplementary Fig. 5a). As previously reported8, EXD2-WT, but not EXD2-NUC, 
exhibited 3’-5’ exonuclease activity on ssDNA (Supplementary Fig. 5b). In addition, 
both EXD2-WT and the WRN-Exo exhibited activity on dsDNA, ssRNA, dsRNA, both 
strands of a DNA/RNA hybrid and several other DNA substrates (Fig. 6b-6d and 
Supplementary Fig. 5d-f). Similar activity was observed with EXD2-C2, although it 
was consistently lower, indicating that stability or selectivity of the enzyme-nucleic 
acid complex may be affected (Fig. 6e and Supplementary Fig. 5f-g). However, when 
MgCl2 was used as a cofactor, both EXD2-WT and EXD2-C2, but not the closely 
related WRN-Exo, showed stronger substrate discrimination with exonuclease 
cleavage observed only on ssRNA or RNA/DNA hybrids (Fig. 6f-i and Supplementary 
Fig. 5h-k). Quantification of multiple experiments revealed that EXD2 had a roughly 
3-fold increase in specific activity on ssRNA compared to ssDNA using MnCl2 but in 
the presence of MgCl2., EXD2 activity on ssDNA and dsDNA substrates was lost, 
reduced on hybrids, but similar on ssRNA (Fig. 6j and Supplementary Fig. 5l). 
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To determine if EXD2 had any binding preference, we performed electrophoretic 
mobility shift assays (EMSA) on fluorescently labeled substrates. We observed a 
clear supershift with ssRNA, but not with ssDNA or hybrid molecules when EXD2 
was added (Fig. 6k). Similarly, EXD2-NUC and EXD2-C2 mutants bound 
preferentially to ssRNA, although the supershift was reduced with EXD2-C2 (Fig. 
6l,m) and WRN-Exo domain did not exhibit any obvious substrate preference 
(Supplementary Fig. 5m). Together these data demonstrate that EXD2 and WRN 
have promiscuous MnCl2-dependent activity on a variety of RNA and DNA substrates 
in vitro, but that EXD2 preferentially binds to ssRNA and can maintain its activity on 
ssRNA in the presence of MgCl2, indicating that it is more likely to be the 
physiological substrate of its activity. 
EXD2/CG6744 influences Drosophila metabolism and development 
Given the influence of EXD2 on mitochondrial function, we examined the impact of 
depleting the D.melanogaster EXD2 ortholog CG6744 (henceforth referred to as 
dExd2) (Supplementary Fig. 6a). Consistent with available data22, two peaks of 
dExd2 expression were observed in control yellow white flies in early embryos (0-4 
hrs) and pupae (WPP) (Supplementary Fig. 6b,c), developmental phases associated 
with high metabolic activity23. We obtained flies with a transposon insertion and 
confirmed dExd2 mRNA depletion in homozygous animals (Fig. 7a). Similar to 
human cells, mtDNA levels were lower in mutant animals and largely rescued by 
NAC (Fig. 7b) and mitochondrial translation rates were reduced in dExd2-deficient 
flies (Fig. 7c,d). Moreover, overexpressed dEXD2 localized extensively to the 
mitochondria of Drosophila S2 cells (Fig. 7e) and dExd2-deficient flies exhibited 
impaired respiration (Fig. 7f) and lower levels of ATP and glutathione (Fig. 7g). 
Embryos and pupae deficient for dExd2 were smaller than controls but appeared 
morphologically normal, suggesting a developmental delay (Fig. 7h), and pupariation 
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times were extended, but could be normalized by NAC or further extended with 
paraquat (PQT), that elevates ROS levels (Fig. 7i). These effects were not due 
exclusively to maternal inheritance of defective mitochondria, as the expected ratio of 
normal to runted animals was observed following breedings from heterozygous 
females, that transmit intact mitochondria to all offspring, with homozygous males 
(Supplementary Fig. 6d). 
EXD2 prevents germ stem cell attrition and regulates lifespan 
As mitochondrial dysfunction and ROS extend or diminish lifespan in different 
experimental settings4-6, we examined the lifespan of dExd2-deficient animals. We 
observed a slight but significant lifespan extension in males that was much more 
dramatic in females and normalized by NAC (Fig. 8a and Supplementary Table 1). In 
adult flies, expression of dExd2 was higher in the ovary than the brain or gut (Fig. 8b) 
and mutants exhibited an accelerated reduction in fecundity that was largely rescued 
by NAC (Fig. 8c). To address the origin of this phenotype, we examined the pool of 
germ stem cells (GSCs) present in control and dExd2-deficient ovaries. As previously 
described, a progressive GSC decline in control flies was observed24, a phenotype 
that was accelerated in dExd2-deficient animals and rescued by NAC (Fig. 8d,e). 
Cytological analysis of dExd2-deficient ovaries revealed a disorganized mitochondrial 
network with highly reduced levels of cytochrome-C, an essential component of the 
ETC, suggesting metabolic collapse in the germarium where the GSCs and somatic 
follicle stem cells reside (Fig. 8f). These results suggest that EXD2 is critical for 
mitochondrial homeostasis in vivo and that it prevents excess ROS production that 
retards normal development and causes the premature attrition of GSCs, reduced 
fecundity and extended lifespan (Supplementary Fig. 6e)25. 
Discussion 
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Our data connects the EXO and HNH-like domains of EXD2 to mitochondrial 
ribosome integrity, translation, OXPHOS activity, and Drosophila germline stem cell 
maintenance and lifespan. We propose that EXD2 acts as a ribonuclease that 
prevents precocious association of mitochondrial mRNAs with the free 28S 
mitoribosomal subunits prior to 55S assembly. This is consistent with the enrichment 
of 28S proteins in BioID-MS, the fractionation pattern of EXD2, its preference for 
ssRNA and the increased mRNA levels co-fractionating with aberrant 28S subunits in 
EXD2-deficient cells. Similar alterations in 28S subunit mobility were observed in 
cells lacking LRPPRC and SLIRP that influence stability and translation of mt-mRNA 
pools26, 27. While we cannot strictly rule out a role for EXD2 in mtRNA processing or 
stability, MitoString28 analysis indicated that the profiles of EXD2-deficient cells were 
highly similar to parental or complemented cells and most known precursor RNA 
processing events occurred normally (Supplementary Fig. 7a,b), indicating that EXD2 
is not likely required for global RNA precursor processing or mt-mRNA levels. 
The EXO and HNH-like domains are both crucial for EXD2 function. Extending earlier 
reports8, we identified additional EXD2 orthologs, defined by EXO and HNH domains 
(Supplementary Fig. 1a-c). Arabidopsis RRP6L3 is a likely EXD2 ortholog with a high 
degree of similarity in the HNH domain, although its EXO domain is more similar to 
RRP6 (exosomal RNAse) than WRN and it contains an additional HRDC domain 
absent in metazoan EXD2s. EXD2 also appears sporadically in some trypanosome 
lineages and in leishmania, EXD2 has an additional Z3H1 type zinc finger not 
present in other species. Thus, EXD2 is widely conserved and at least 3 major 
domain configurations exist, potentially reflecting specialization of function in those 
organisms.  
Our data suggests the HNH-like motif influences stable binding of EXD2 to ssRNA 
and the 28S (Fig. 4,5), reflected by the absence of EXD2-SF-C2 in 28S fractions (Fig. 
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5a) and its reduced RNA binding. The EXD2 HNH-like domain lacks conserved DH 
catalytic residues required for activity in other HNH-endonucleases (Supplementary 
Fig. 1d). Notably, in fold and function assignment searches (FFAS), several of the 
highest scoring HNH domains belong to proteins involved in chaperoning assembly 
and insertion of membrane complexes (DotN) or electron transport (NapB), 
suggesting a diverse repertoire of potential functions for this domain (Supplementary 
Fig. 1d). 
Both human and Drosophila EXD2 were identified in a genome wide siRNA screen 
for host factors that support Dengue RNA virus replication but a specific role in the 
viral lifecycle has not been reported29. EXD2 was also implicated in DNA repair, 
reported to localize to nuclear chromatin and interact with the DNA resection 
machinery and identified on collapsed replication forks in an iPOND-MS screen7-10, 30. 
However, 11 mitochondrial proteins, including 5 mitoribosome proteins, were also 
identified in the iPOND-MS screen30 with comparable scores, and using the reported 
fractionation methods8, we readily identify EXD2 in chromatin fractions 
(Supplementary Fig. 7c) but they were highly contaminated with mitochondria, points 
that should be considered in light of the data reported here. We do not detect EXD2 
in the nucleus (Fig. 1 and Supplementary Fig. 1h) and overexpressed human and fly 
EXD2 localizes primarily to mitochondria in IF with no clear nuclear staining (Figs. 1, 
4 and 7), consistent also with the cytoplasmic localization reported for Arabidopsis 
RRP6L331. Moreover, in an unbiased proteomics approach, we identified almost 
exclusively mitochondrial proteins, none of which have been implicated in DNA repair 
or replication, except for POLD4 (POLDIP2) and ATR, which also have mitochondrial 
roles (Fig. 4c and Supplementary Table 2)32, 33.  
Consistent with previous reports8, we observed robust 3’-5’ exonuclease activity but 
both EXD2 and WRN showed activity on all DNA and RNA substrates tested (Fig. 6 
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and Supplementary Fig. 5) when MnCl2 was used in reactions. In contrast, EXD2 
showed clear binding and activity on ssRNA in the presence of MgCl2, suggesting its 
physiological substrate is RNA. Additionally, we did not observe defective RPA focus 
formation (Supplementary Fig. 7d,e) or DNA damage sensitivity in EXD2-deficient 
cells using several cell line backgrounds controlled with complementation 
(Supplementary Fig. 7f-h). We believe that our data strongly indicates that the 
primary role of EXD2 is to govern mitochondrial ribosome mRNA loading, translation 
and ATP production through its RNAse, and potentially other activities. However we 
cannot strictly rule out a DNA replication/repair role that we have not detected due to 
differences in technical conditions or cell line backgrounds. Notably, phenotypes 
associated with some translational regulators include defects in mitochondrial and 
nuclear genome maintenance34, there are examples of DNA repair enzyme families 
with key roles in translational regulation35 and numerous DNA repair nucleases (ex. 
FEN1 and DNA2) localize to both the nucleus and mitochondria36, 37. 
ROS levels, reproductive capacity, abundance and activity of OXPHOS components 
and global translation have all been shown to be major factors influencing lifespan in 
numerous organisms4, 6, 38-40. Depletion of mitochondrial translational regulators in 
S.cerevisae extends lifespan in a Sir2 dependent manner41 but we did not observe 
alterations in Sir2 mRNA in dExd2-deficient flies and lifespan extension in females 
was independent of calorie restriction (CR), that is also Sir2 dependent 
(Supplementary Fig. 7i,j)42. We propose that the dramatic lifespan extension in 
dExd2-deficient females is primarily the result of ROS-mediated, premature attrition 
of the GSC pool and loss of fecundity (Supplementary Fig. 6e), consistent with dExd2 
expression patterns, the rescue of GSC attrition, fecundity and lifespan with NAC 
treatment, the reduced respiration observed in dExd2-deficient flies and the close 
correlation between age of GSC loss and lifespan extension (Fig. 8). An inverse 
	 15	
relationship between lifespan and reproductive capacity was reported in several 
organisms, including C.elegans and Drosophila25. While multiple mechanisms have 
been proposed, including elevated ROS and antagonistic GSC to soma crosstalk, the 
precise nature of the signal that influences lifespan remains to be clarified43. 
While it remains unclear if EXD2 influences mammalian fertility or lifespan, analysis 
of mRNAs enriched in germ plasm of Xenopus, that is rich in mitochondria and RNA 
binding proteins, identified xEXD244, indicating that it could play a similar role in the 
vertebrate GSC niche. Patients with interstitial deletions in chromosome 14q24, that 
include EXD2 and 18 neighboring genes, have been reported to have congenital 
heart defects, brachydactyly and intellectual disability45, indicating that EXD2 loss 
may influence human development. However, the individual contribution of EXD2 
deficiency to these pathologies remains unclear. The precise control of mtDNA levels, 
RNA processing, ribosome assembly, translation and the dynamic composition and 
molecular regulation of OXPHOS complexes in mammals is critical for normal 
metabolism and healthy aging1. Our results, and those of others, suggest that many 
additional regulators of these processes have yet to be identified and their 
characterization will further enhance our understanding of mitochondrial regulation 
and its role in ageing. 
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Figures legends 
Figure 1: EXD2 is a mitochondrial protein. (a) Immunofluorescence of 
endogenous EXD2 in U2OS cells revealed extensive co-localization with the 
mitochondrial TOM20 protein. EXD2 localization was unaltered by treatment with 
1μM camptothecin (CPT) to induce DNA damage (lower panels). Scale bar = 20µm. 
(b) EXD2 contains a mitochondrial-targeting signal (MTS) that is necessary and 
sufficient for mitochondrial localization. Amino acids 1-61 of EXD2 are sufficient to 
localize GFP to mitochondria (bottom panel). Deletion of EXD2 aa 1-61 leads to 
diffuse nuclear-cytoplasmic localization (middle panels). Scale bar = 15µm. Panels in 
a, b represent 1 out of 5 experiments. (c) Western blot of GFP fusion proteins with 
expected sizes indicated. Note poor expression/destabilization of ∆MTS-GFP. 
Arrowheads indicate the protein of the corresponding label color. (d) Subcellular 
fractionation of EXD2 (hatched boxes) in the presence or absence of 1μM CPT 
indicated exclusively mitochondrial localization. Data represent 1 out of 3 
experiments (e) Transmission electron microscopy (TEM) indicated mitochondrial 
(dashed outlines) localization of EXD2-SF-WT. Scale bar = 200nm. See 
Supplementary Fig. 1f,g for additional examples. (f) Western blot of mitochondria 
isolated from U2OS cells treated with 50µg/ml proteinase-K (PK) in the presence or 
absence of Triton X-100 shows that EXD2 is resistant, similar to OXPHOS subunit 
ATP5A, indicating IM and/or matrix localization Data in e, f represent 1 out of 2 
experiments. Uncropped blots shown in Supplementary Fig. 9.  
Figure 2: EXD2 is required for metabolic homeostasis. (a) Quantitative real time 
PCR (qRT-PCR) confirmed reduction of EXD2 mRNA following expression of stable 
shRNAs against EXD2. Averages from 7 independent experiments in triplicate are 
plotted (n=7). (b) Confirmation of reduced EXD2 protein levels in cells expressing 
shRNAs against EXD2. Actin serves as a loading control. Data represent 1 out of 5 
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experiments. (c) Heatmap representation of metabolite fold changes (FC) 
significantly altered by EXD2 (shEXD2-22) depletion compared to control (shCont) 
cells is shown. Values represent mean of n=5 independent samples. Depicted 
metabolites have a FC >1.3 with an adjusted p-value of <0.01 (t-test). (d) Pathway 
enrichment analysis of metabolite differences from MS-data and 1H-NMR metabolite 
profiling. X-axis represents Pathway Impact calculated from topological analysis 
based on the centrality measures of individual metabolites in a given metabolic 
network and the y-axis represents FDR p-values from a hypergeometric test. 
Overrepresented pathways with higher impact are highlighted with darker color and 
size. (e) Metabolic summary chart showing active pathways in U2OS cell lines, as 
revealed by 1H-NMR positional enrichment by proton analysis (PEPA)13. Metabolic 
structures are depicted with red and blue dots indicating fates of [U-13C]glucose or 
[U-13C]glutamine respectively. FC of metabolites identified from both approaches are 
indicated in red (up) or green (down) text in accordance with the heatmap. (f) EXD2 
depletion impairs glucose usage. Examples of 1H-NMR metabolite profiling predicted 
significant fractional enrichments. Red and blue dots represent individual F values 
calculated using [U-13C]glucose or [U-13C]glutamine, respectively. Results from n=3 
independent cultures plotted as mean(SD) with individual values shown. Source data 
for the figure is provided in Supplementary Table 1 and unprocessed scans for 2b in 
Supplementary Fig. 9. 
Figure 3: Characterization of EXD2 deficient cells. (a) Glutathione (GSH or 
GSSG) levels in MDA-MB-231 cells measured by liquid chromatography-mass 
spectrometry (LC-MS) -/+ NAC or treatment with CAP or FCCP. Values of n=3 (WT) 
or n=4 (all others) independent cultures with mean(SD) (**p<0.01, unpaired t-test, 
two-tailed). Color key applies to all panels in figure. (b) ROS levels in MDA-MB-231 
cells measured with MitoSOX red. Controls and gating examples in Supplementary 
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Fig. 8. Averages of n=3 independent experiments with mean(SD) (**p<0.01, 
***p<0.001, unpaired t-test, two-tailed). (c) MtDNA levels determined using qRT-PCR 
in U2OS cells in presence or absence of NAC. Averages of n=3 independent 
experiments with mean(SD). Similar results obtained in multiple cell lines 
(Supplementary Figs. 2c and 2d). Statistical analysis of 3b-c: one-way ANOVA with 
Dunnet’s test (***p<0.001, **p<0.01, *p<0.05). (d) Mitochondrial mass measured by 
MitoTracker Green FM staining of U2OS cells. Averages from n=3 independent 
experiments with mean(SD) plotted. (e) Mitochondrial mass measured by western for 
VDAC1 levels Data represent 1 out of 3 experiments.  (f-i) EXD2-deficient cells grow 
normally in rich media (f) but glutamine removal severely impaired growth (g). NAC 
did not rescue growth in absence of glutamine (h) but slightly reduced growth in all 
lines (i). Mean(SD) of n=3 independent experiments shown. (j-k) OCR analysis 
(mitochondrial stress test: Oligomycin, FCCP and Antimycin+Rotenone) revealed 
decreased basal, ATP-linked and maximal respiration in EXD2-deficient cells and 
increased ECAR (glycolysis stress test: Glucose, Oligomycin and 2-DG) that was 
rescued by EXD2-SF-WT but not NUC or C2 mutants in U2OS cells. Red arrows 
indicate treatment between category measurements. All time course values from 
quadruplicate cultures of 2 independent experiments with mean are shown for j-k. (l) 
Influence of NAC on OCR. Values from quadruplicate cultures of 2 independent 
experiments with mean are shown. Similar results in MDA-MB-231 shown in 
Supplementary Fig. 3h-j. (m) U2OS cells treated with glucose to distinguish OCR 
from glutaminolysis or glycolysis. All time course values from quadruplicate cultures 
of n=2 independent experiments with mean are shown. (n) Lower ATP levels in 
EXD2-KO1 U2OS cells than WT or complemented cells. Averages from n=3 
independent cultures shown with mean(SD) (**p<0.0070 and 0.0029, unpaired t-test, 
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two-tailed). Source data for figure and statistical information in Supplementary Table 
1 and uncropped western blots in Supplementary Figure 9. 
Figure 4:  EXD2 interacts with Complex I and the mitoribosome. (a) Expression 
of FLAG-tagged BirA*, EXD2-C2-BirA* or EXD2-WT-BirA* fusion proteins with or 
without 24 hours of biotin labeling. BirA* expressing control cells showed diffuse 
nucleo-cytoplasmic streptavidin signal while Streptavidin staining was predominantly 
cytoplasmic for EXD2-C2-BirA* or EXD2-WT-BirA* and overlapped extensively with 
the mitochondrial marker TOM20. Scale bar = 10µm. (b) Graphical representation of 
the subcellular localization of proximity interactors in EXD2-WT-BirA* or EXD2-C2-
BirA* expressing cells. Summarized results provided in Supplementary Table 2. (c) 
EXD2 associates with primarily mitochondrial proteins and interactors are enriched 
for Complex I and the mitoribosome. Proteins are color-coded based on the statistical 
analysis (see legend and Supplementary Table 2) and those involved in human 
hereditary diseases are circled in yellow. (d) EXD2 interacts with DAP3 in IP-western, 
but not with VDAC or MRPL3, and the interaction is severely reduced in cells 
expressing the EXD2-C2 mutant. Results from immunoprecipitation-western blotting 
of U2OS cell extracts are shown. Data represent 1 out of 3 experiments. Uncropped 
western blots shown in Supplementary Figure 9.  (e) Immunofluorescence analysis of 
endogenous human EXD2 in U2OS cells using confocal microscopy revealed 
extensive co-localization with the mitoribosome protein MRPL12. Scale bar = 10µm. 
Images in a and e represent more than 25 cells analyzed in two experiments. 
Figure 5: EXD2 prevents aberrant mRNA association with the mitoribosome 
and facilitates translation. (a). Sucrose gradient fractionation shows distribution of 
markers of the 28S (DAP3) and 39S (MRPL12) mitoribosome. EXD2 co-sediments 
with the 28S and assembled 55S mitoribosome. EXD2-KO1 and EXD2-SF-C2 cells 
show differences in 28S distribution (compare red boxes). Quantification shown for 
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WT and EXD2-KO1 (right panel) with individual values of n=3 independent 
experiments shown with mean(SD). Quantification of EXD2-SF-C2 with individual 
values of n=2 independent experiments shown with mean. Graphical representation 
of detected components shown below each plot. (b) QRT-PCR analysis of the 
sedimentation profile of the indicated mitochondrial transcripts in WT, EXD2-KO1 and 
EXD2-SF-C2 cells. The abundance of transcripts in each fraction is shown as a 
percentage of the total levels. The distribution of fractions containing the 28S, 39S 
and 55S detected by western blot shown for reference. Quantification of n=3 
independent experiments is shown for WT and EXD2-KO1 with all values and the 
mean(SD) indicated. Quantification of n=2 independent experiments is shown for 
EXD2-C2 with individual values and mean indicated. (c) EXD2 is required for efficient 
mitochondrial translation. Phosphorimager scans of 35S-Methionine labeled 
mitochondrial translation products separated by SDS-PAGE and blotted to PVDF 
membranes shown for the indicated cell lines. Subsequent western blotting for 
GAPDH was performed to ensure equal loading. Approximate size of mitochondrial 
translation products is indicated to right of gel. (d) Quantification of n=7 independent 
experiments compared to the WT sample is plotted with mean(SD). ***p<0.0001, 
unpaired t-test, two-tailed. (e) The WT but not the NUC and C2 mutant forms of 
EXD2 can rescue the translation defect of cells lacking EXD2. (f) The mitochondrial 
translation defect is not rescued by the administration of NAC to the culture medium. 
Data in e, f represent one out of 3 experiments. Controls treated with CAP, to block 
mitochondrial translation, or CAP without emetine, to allow only cytoplasmic 
translation, are shown. Additional examples used for quantification in Supplementary 
Fig. 4, source data and statistics in Supplementary Table 1 and uncropped blots in 
Supplementary Fig. 9. 
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Figure 6: EXD2 preferentially targets ssRNA. (a) Schematic of proteins used in 
biochemical analysis. (b) EXD2-WT (5-80 nM) or EXD2-NUC (40-80 nM) were 
incubated with 20nM fluorescently labelled ssDNA or dsDNA or (c) 20nM RNA/DNA 
(FAM/Cy5) hybrid in the presence of 10mM MnCl2. Bold font indicates molecule 
visualized and sepia panel is the same gel scanned with a second laser for Cy5 
labeled DNA. (d) EXD2-WT (5-80nM) was incubated with a dsRNA FAM substrate 
(forward) in the presence of 10mM MnCl2. (e) EXD2-C1/2 (5-80 nM) was incubated 
with 20nM fluorescently labelled ssRNA or RNA/DNA hybrid in the presence of 
10mM MnCl2. (f) EXD2-WT (5-80nM) or EXD2-NUC (40-80nM) was incubated with 
20nM fluorescently labelled ssDNA or dsDNA or (g) 20nM RNA/DNA (FAM/Cy5) 
hybrid in the presence of 10mM MgCl2. (h) EXD2-WT (5-80nM) was incubated with a 
dsRNA FAM substrate (forward) in the presence of 10mM MgCl2. (i) EXD2-C1/2 (5-
80 nM) was incubated with 20nM fluorescently labelled ssRNA or RNA/DNA hybrid in 
the presence of 10mM MgCl2. All reactions in (b-i) were carried out for 30 min at 
37°C before being separated on an 18% polyacrylamide urea TBE gel and 30 bp 
indicated with black arrowhead (b-i). (j) Quantification of specific activity (nM 
substrate cleavage/nM protein per minute) of EXD2-WT on indicated substrates in 
the presence of MgCl2 or MnCl2. Data compiled from n=3 independent experiments 
and all values with mean(SD) are shown. (k) EXD2-WT (20-310 nM), (l) EXD2-NUC 
(20-310 nM), (m) EXD2-C1/2 (20-310 nM) were incubated with 20nM fluorescently 
labelled ssDNA, ssRNA, RNA/DNA hybrid or dsDNA, 30 min on ice. Red arrow 
indicates the protein/nucleic acid complex formed with ssRNA and reduced with the 
EXD2-C1/2 mutant and black arrowhead = 40 bp (k-m). Data in b-c, e-g, i, k-l, are 
representative of three experiments; 6d, 6h, 6m, are representative of two 
experiments. Source data in Supplementary Table 1 and additional analysis and 
uncropped gels in Supplementary Figs. 5 and 9, respectively. 
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Figure 7: Metabolic and developmental defects in dExd2 deficient flies. (a) 
Reduced dExd2 expression in dExd2EY03872 flies compared with control (yellow white, 
yw) measured by qRT-PCR. Averages from n=3 independent experiments plotted 
with mean(SD) (***p=0.0002 and 0.0003, unpaired t-test, two-tailed). (b) mtDNA 
levels analyzed using qRT-PCR in flies reared in food +/- NAC. Averages from n=3 
experiments plotted with mean (SD). **p=0.0083 female, **p=0.0013 male, unpaired 
t-test, two-tailed. (c) Phosphorimager scan of mitochondrial translation products. 
Western blotting for VDAC shows equal loading. (d) Quantification of n=3 
independent experiments compared to WT sample with mean(SD) shown with 
individual values. **p=0.0024, unpaired t-test, two-tailed. (e) Confocal 
immunofluorescence of exogenously expressed dEXD2-BirA*-FLAG or BirA*-FLAG 
in Drosophila S2 cells. Extensive co-localization of EXD2-BirA*-FLAG but not BirA*-
FLAG is observed with the mitochondrial protein ATP5A. Scale bar=0.2 µm. Data 
represent 30 cells from 2 experiments. (f) Reduced oxygen consumption in dExd2-
deficient flies is not rescued with NAC treatment. Measurements from n=4 or n=3 
(NAC samples) independent experiments are plotted with mean(SD). *p<0.05, 
***p<0.001, one way ANOVA with Dunnet’s test. (g) LC-MS analysis of the indicated 
metabolites in 1 week old flies reared on normal food or food containing NAC. n=4 
independent biological replicates plotted with the mean(SD). (h) dExd2EY03872 
embryos and pupae are smaller than controls. Individual values and mean(SD) from 
n=100 embryos and n=31 pupae are shown (***p<0.0001, t-test two-tailed). A 
representative example of pupae of each genotype is shown, scale bar=500µm. (i) 
Delayed pupariation in dExd2EY03872 flies is rescued by NAC and enhanced by PQT at 
doses that do not strongly affect controls. Mean(SD) compiled from n=3 independent 
experiments with 40 flies per point is plotted. Source data for figure and additional 
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statistical information in Supplementary Table 1 and uncropped blots in 
Supplementary Figure 9. 
Figure 8: Germline stem cell attrition and increased lifespan in dExd2 deficient 
flies. (a) Significantly increased lifespan in dExd2EY03872 flies compared to controls, 
particularly for females. NAC normalizes lifespan of dExd2-deficient females. 
Mean(SD) was compiled from n=3 independent experiments, each using 60 flies. 
***p<4.03x10-10 for males and ***p<2.22x10-16 for females, proportional hazard-Cox 
model. (b) QRT-PCR analysis of different Drosophila tissues shows high dExd2 
mRNA levels in the ovaries of control flies compared to other tissues. Values from 
n=3 independent experiments are plotted with mean(SD). (c) Fecundity was reduced 
in dExd2EY03872 flies and partially rescued by NAC. A total of 60 flies were used for 
each group and mean(SD) shown. (d) Age dependent attrition of GSCs in 
dExd2EY03872 flies was rescued by NAC. GSCs were identified by Hts staining and 
indicated by white arrows. Scale bar = 20µm. (e) Quantification of GSCs of each 
genotype for the indicated ages +/- NAC treatment. Mean was compiled from n=15 
independent germaria at each time point and mean(SD) shown. Statistical analysis 
performed using the proportional odds cumulative link model (***p=1.38E-08 for week 
7). (f) Immunofluorescence analysis revealed a strong decrease in Cytochrome-C 
(Cyt-C) levels and disorganized ATP synthase patterns (ATP5A) in dExd2EY03872 
mutant germaria. Scale bar=20 µm. Source data and additional statistical analysis in 
Supplementary Table 1. 
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Methods 
Generation of expression constructs 
Human EXD2 was amplified from U2OS cell cDNA, sequenced and cloned into 
pENTR/D-TOPO (Invitrogen) following manufacturer’s protocol. EXD2 was subcloned 
using LR clonase into the retroviral vector pLPC-C-SF-TAP (SF=Strep-FLAG) 
generated by subcloning the C-SF-TAP cassette (a kind gift from C.J. Gloeckner46) 
into the pLPC-N-Myc plasmid (a kind gift from T. de Lange, Addgene plasmid 
#12540). EXD2 mutants were generated using the QuikChange Lightning Site-
Directed Mutagenesis Kit (Agilent Technologies 210518-5) according to 
manufacturer’s instructions. Clones were purified using the PureLink® Quick Plasmid 
Miniprep Kit (Invitrogen) and the sequence of constructs confirmed. Large-scale 
plasmid purification was performed using the PureYield™ Plasmid Maxiprep System 
(Promega). Primers sequences are provided in Supplementary Table 3. 
Human cell culture 
Human cell lines (U2OS, HEK293T, AD293, MDA-MB-231 and RPE1) were cultured 
in Dulbecco’s modified Eagle Medium (DMEM, Invitrogen 41966) supplemented with 
10% (v/v) fetal bovine serum (FBS; Sigma F7524-500ML) and 100U/ml 
penicillin/streptomycin (P/S; Reactiva, 01030311B000) in 5% CO2. In some 
experiments cells were treated with 100μg/ml Chloramphenicol (CAP) (Sigma, 
C3175), 25µM carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) 
(Sigma, C2920) or 5 mM N-acetylcysteine (NAC) (Sigma, A9165).  
Generation of retrovirus/lentivirus and stable cell lines 
For viral production, HEK293T cells were seeded in 10cm plates 24 h prior to 
transfection with polyethyleneimide (PEI; Polysciences Euro GMBH). For lentivirus, a 
mixture of 10μg lentivirus-shRNA, 2μg REV, 6μg RSV-RRE and 2μg VSV-G 
plasmids47 with 78μl PEI and 900μl 150mM NaCl was added to the cell culture media 
and for retrovirus, a mixture of 10μg retroviral vector DNA, 9μg GAG-Pol (pCL-Eco)48 
and 1μg VSV-G plasmids with 78μl PEI and 900μl 150mM NaCl was added to the 
cell culture media. In both cases, 16 h later, cells were washed in PBS and the media 
replaced. 48 h later the viral supernatant was removed, cleared with a 0.45μM filter, 
and incubated with target cells. 3 days after infection, cells were selected with 
Puromycin (Sigma, P8833-25MG) for 5 days and maintained subsequently in the 
normal growth medium. Lentivirus shRNA constructs were purchased from the Sigma 
MISSION lentiviral library against EXD2 (sh31: TRCN0000051631 (NM_018199.1-
155s1c1), sh22: TRCN0000327822 (NM_018199.2-1001s21c1) and shRNA against 
GFP (SCH005) and sh-non-targeter (shNT, SHC016) were used as controls.  
Generation of EXD2 knockout cells with CRISPR/CAS9 
Forward and reverse oligonucleotides containing the guide sequence were annealed 
and cloned into the pX330-U6-Chimeric_BB-CBh-hSpCas9 (a gift from Feng Zhang, 
Addgene plasmid #42230)15 modified to coexpresses EGFP (a gift from C.Cortina 
and E.Batlle) and this was transfected into U2OS and MDA-MB-231 cells using 
Lipofectamine® 2000 Transfection Reagent (ThermoFisher). GFP-positive cells were 
sorted 24 h after transfection (BD FACSAria III SORP) and expanded from single 
cells. Screening for EXD2-KO cells was carried out by western blotting. Two clones 
each of U2OS and MDA-MB-231 showing complete loss of EXD2 protein were 
selected for further phenotypic analysis. 
Isolation of DNA, RNA and cDNA preparation 
For DNA isolation of human cancer cell lines, 1,000,000 cells were plated on 10 cm 
plates and collected 24 h later in 515μl of lysis buffer (75mM NaCl, 50mM EDTA, 
0.02% SDS, 0.4mg/ml Proteinase-K (PK)). Lysate was transferred to 1.5ml 
Eppendorf tubes and incubated at 50°C for 2 h. 1 volume of isopropanol was added 
and mixed and incubated at 4°C O/N. Tubes were centrifuged at 8,500g for 30min at 
4°C and pellets washed with 70% EtOH and air-dried. DNA was resuspended in TE 
and diluted to 100ng/ml for qPCR. Drosophila melanogaster DNA was obtained from 
adult flies that were snap frozen in liquid nitrogen and the abdomens homogenized 
with a pestle in grinding buffer (0.2M sucrose, 0.1M Tris pH 9.2, 50mM EDTA and 
0.5% SDS) and incubated at 65°C for 10 min. KAc was added to a final concentration 
of 5M and the samples were incubated on ice for 20min. DNA was precipitated with 
Phenol/Chloroform/Ethanol. Total RNA was isolated using the PureLink RNA mini kit 
(Ambion) according to manufacturers instructions. 1μg of total RNA was used as a 
template for cDNA synthesis using a High Capacity RNA-to-cDNA Kit (ThermoFisher). 
Quantitative real time PCR (qRT-PCR) 
Real-time quantitative PCR was performed using a Step-One-Plus real-time PCR 
(Applied Biosystems) Instrument and quantified with the comparative CT method. 
Amplification was performed using Power SYBR Green PCR Master Mix (Applied 
Biosystems, 4309155). Analysis of EXD2 mRNA levels was done using Taqman 
probes from Applied Biosystems (EXD2 Hs00217045_m1, ACTB 4352935E) 
together with Taqman master mix (Applied Biosystems). Primers used are provided 
in Supplementary Table 3.  
Flow cytometry based assays for mitochondrial function 
For the analysis of mitochondrial mass, 150,000 cells were seeded in 6-well plates in 
duplicate 24h prior to analysis. Cells were incubated for 30min with 250nM 
MitoTracker Green FM or Deep Red probes (ThermoFisher) in normal growth 
medium at 37°C. Cells were trypsinized and washed with warm PBS once, stained 
with 500 nM 4’,6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI) and analyzed by 
flow cytometry immediately. To detect intracellular and mitochondrial ROS production, 
150,000 cells were seeded in 6-well plates in duplicate 24 h prior to analysis. Cells 
were incubated at 37°C for 30 min in 5μM MitoSox (Molecular Probes, M36008) and 
then trypsinized and washed with warm PBS once and analyzed immediately by flow 
cytometry. Data was collected with a Gallios using Kaluza for Gallios software 
(Beckman Coulter) and analyzed using FlowJo v9.9.6 (FlowJo LLC). Data was 
plotted and statistically analyzed in Prism7 and examples provided in Supplementary 
Fig. 8.  
Immunofluorescence 
For immunofluorescence, cells were fixed with 4% formaldehyde for 10 min at room 
temperature (RT). After two washes with PBS, cells were permeabilized with PBS 
containing 2% Triton X-100 for 10 min at RT. Cell were washed twice with PBS and 
incubated with first antibody (1:500) in PBS-T containing 10% FBS for 1 h at RT. 
After two washes with PBS-T, cells were incubated with secondary antibody (1:500) 
in PBS-T containing 10% FBS and DAPI for 1 h at RT. Slides were rinsed in PBS-T, 
washed twice for 5 min in PBS-T and mounted with Vectashield (Vector Laboratories, 
H-1000). Drosophila embryos (0-15h) were collected, dechorionated with bleach for 
90s and rinsed with 0.1% Triton X-100. Embryos were incubated in a solution 
containing 4% formaldehyde and heptane (1:1) for 20 min in a rotator at RT. 
Formaldehyde was replaced with methanol, samples were vortexed for 20 sec and 
the embryos were transferred to new vials and washed extensively with PBS-T 
containing 0.3% bovine serum albumin (BSA). Samples were incubated with primary 
antibody for 4 h at RT and after two washes with PBS-T they were incubated with 
secondary antibody for 2 h at RT, followed by an incubation with DAPI for 15 min at 
RT. Embryos were rinsed in PBS-T, washed twice for 5 min in PBS-T containing 
0.3% BSA and mounted with Fluoromount (Sigma, F4680). Adult ovaries from 
Drosophila were dissected in Schneider medium and fixed in 4% formaldehyde in 
PBS for 20 min at RT. After washing with PBS, they were permeabilized with 1% 
Triton X-100 in PBS for 2 h and then incubated in PBS-T (1% (w/v) BSA, 0.2% Triton 
X-100, PBS) for 1 h. Ovaries were then incubated with primary antibodies diluted in 
PBS-T O/N at 4°C. The next day, they were washed with PBS, incubated in the dark 
with secondary antibodies diluted in PBS-T for 3 h at RT and further stained with 
rhodamine-phalloidin (Biotium, #00027) and Hoechst (Sigma) for 20 min. After final 
washes with PBS, ovaries were mounted in Vectashield (Vector Laboratories, H-
1000) Images were acquired with a Leica SPE confocal microscope and cropped in 
ImageJ49. Depth (z) thresholds were set accordingly in order to apprehend the entire 
architecture. In some cases, brightness and contrast were adjusted in ImageJ 
(v1.49b). Any changes were applied to all images equally for direct comparison. 
Antibodies used are provided in Supplementary Table 4. 
Protein lysates, fractionation and Western blotting 
Cells were rinsed with PBS and collected in lysis buffer (50mM HEPES, 16mM NaCl, 
1% NP-40, 0.5% DOC, 0.1% SDS, 1x protease inhibitor cocktail (Roche, 
04693132001) and phosphatase inhibitor cocktail (Sigma, P5726). Samples were 
sonicated (15s-15s) for 30 min, spun down at 4°C for 20 min at 12,000xg and 
quantified with the DC Protein assay (Biorad, 500-0114). 50μg of total protein was 
boiled 10 min with loading dye (50mM Tris-Cl (pH 6.8), 0.3% SDS, 0.1% 
bromophenol blue, 10% glycerol, 0.4% ß-mercaptoethanol) and separated by SDS-
PAGE followed by electrophoretic transfer to PVDF membrane (Millipore). 
Membranes were blocked for 20 min in PBS-T with 5% dry milk and primary antibody 
(in PBS-T with 5% dry milk) was added for either 1 hour at RT or O/N at 4°C. 
Membranes were washed 3X in PBS-T and incubated with secondary antibody (in 
PBS-T with 5% dry milk) 1 h at RT. After 3X PBS-T washes, ECL-reagent 
(Amersham, RPN2132) and X-ray film (Fujifilm, 47410 19236) were used to detect 
signal. Antibodies used are listed in Supplementary Table 4. Separation of cellular 
compartments was performed according to manufacturers instructions with Standard 
Cell Fractionation Kit (Abcam, ab109719). Further HCl treatment of the nuclear 
fractions was used for chromatin extraction. Alternative chromatin fractionation 
(Supplementary Fig. 7c) was performed as described previously8. U2OS cells were 
resuspended in buffer A (10mM HEPES-KOH pH=7.9, 10mM KCl, 1.5mM MgCl2, 
340mM sucrose, 10% glycerol, 1mM DTT, 1x protease inhibitor cocktail (Roche, 
04693132001) and phosphatase inhibitor cocktail (Sigma, P5726)) and Triton-X100 
was added to a final concentration of 0.1%. After incubation on ice for 5 min, samples 
were centrifuged at 1300xg for 4 min. Pelleted nuclei were washed with buffer A, 
resuspended in buffer B (3mM EDTA, 0.2mM EGTA, 1mM DTT, 1x protease inhibitor 
cocktail (Roche, 04693132001) and phosphatase inhibitor cocktail (Sigma, P5726)) 
and lysed for 20 min on ice. After centrifugation at 1,700xg for 5 min, the supernatant 
(nuclear soluble fraction) was collected, and the pellet (chromatin fraction) was 
washed with buffer B, resuspended in urea buffer (9M urea, 50mM Tris-HCl pH=7.3) 
and sonicated. 
Submitochondrial fractionation 
PK treatment of mitochondria was performed as previously described50. Briefly, 
U2OS cells were homogenized in ice-cold MB buffer (210mM mannitol, 70mM 
sucrose, 10mM HEPES-KOH pH 7.4 and 1mM EDTA) with a glass dounce 
homogenizer (40 tight strokes) and mitochondria were obtained by differential 
centrifugation. To test protease accessibility, 100μg of mitochondria were 
resuspended in 200μl of MB buffer, swelling buffer (10mM HEPES-KOH pH7.4), or 
MB + 0.2% (v/v) Triton X-100. PK was added to a final concentration of 50μg/ml and 
the samples were incubated on ice for 30 min. Proteolysis was stopped by adding 
2mM phenylmethylsulphonyl fluoride. Samples were precipitated with trichloro-acetic 
acid (TCA; Sigma, T6399) and analyzed by SDS-PAGE. Analysis of differential 
protein retention after FCCP treatment was performed by treating U2OS cells with 
25μM FCCP for 24 hours. Separation of cellular compartments was performed 
according to manufacturers instructions with Standard Cell Fractionation Kit (Abcam, 
ab109719). Further HCl treatment of the nuclear fractions was used for chromatin 
extraction. 
Metabolomic analysis of human cell lines 
A combination of LC-MS and GC-MS analysis performed by Metabolon 
(www.metabolon.com)12 was used for the detection of a total of 253 metabolites in 
cell extracts. Analysis was performed using 5 independent cultures of control U2OS 
cells selected with a stable shRNA against GFP (shCont) or EXD2 (shEXD2-22). 
Cells were collected, snap frozen and metabolites were extracted using a proprietary 
series of organic and aqueous extractions and divided into two fractions for analysis 
using liquid chromatography/mass spectrometry (LC/MS, LC/MS2) and gas 
chromatography/mass spectrometry (GC/MS). LC/MS was based on a Waters 
ACQUITY UPLC and a Thermo-Finnigan LTQ mass spectrometer, which consisted 
of an electrospray ionization (ESI) source and linear ion-trap (LIT) mass analyzer. 
Samples for GC/MS were re-dried under vacuum desiccation for a minimum of 24 h 
prior and derivatized under dried nitrogen using bistrimethyl-silyl-triflouroacetamide 
(BSTFA; Sigma, 33024). The GC column was 5% phenyl and the temperature ramp 
from 40°C to 300°C in a 16 min period. Samples were analyzed on a Thermo-
Finnigan Trace DSQ fast-scanning single-quadrupole mass spectrometer using 
electron impact ionization.  
For 13C stable isotope tracer analysis, 6xE6 U2OS cells stably expressing the 
indicated shRNA constructs were seeded on 15cm tissue culture plates in triplicate. 
The following day, cells were rinsed 2X in PBS and 20ml media (DMEM w/o glucose, 
w/o glutamine, 10% FBS, 1x P/S) containing 5mM glucose (unlabeled or [U13C6]-D-
Glucose, Cambridge Isotope Laboratories, CLM-1396-1) or 2mM glutamine 
(unlabeled or [U-13C5]-Glutamine, Cambridge Isotope Laboratories, CLM-1822-H-0.1) 
was added to the cells for 6 h. Cells were collected by trypsinization and 10xE6 cells 
were pelleted and snap-frozen, after which the metabolites were extracted into 
solvent by adding 2ml of ice-cold chloroform/methanol (2:1 v/v). The suspension was 
bath-sonicated for 3 min, and 2ml of cold water was added and then, 1ml of 
chloroform/methanol (2:1 v/v) was added to the samples followed by bath-sonication 
for 3 min. Cell lysates were centrifuged (5,000xg for 15 min at 4°C) and the aqueous 
phase transferred into a new tube. Samples were frozen until analysis using 
Positional Enrichment by Proton Analysis (PEPA)13. PEPA detects the position of 
carbon label in isotopically enriched metabolites and quantifies fractional enrichment 
by indirect determination of 13C-satellite peaks using 1D-1H-NMR spectra.	
Liquid chromatography-mass spectrometry (LC-MS) analyses 
Metabolites were extracted from snap frozen cell pellets by adding 200µL of cold 
acetonitrile (ACN)/H2O (1:1) with 1% meta-phosphoric acid (MPA) and 0.1% formic 
acid (previously filtered, 1:1 v/v). Samples were vortexed for 30 sec and immersed in 
liquid N2 to disrupt cell membranes followed by 30 sec of bath-sonication and these 
two steps were repeated 3 times. Then, samples were incubated at -20ºC for 2 h. 
Finally, samples were centrifuged at 17,000xg for 15 min and the supernatant was 
collected into a LC-MS vial. Samples were injected in a UHPLC system (1290 
Agilent) coupled to a triple quadrupole (QqQ) MS (6490 Agilent Technologies) 
operated in multiple reaction monitoring (MRM) and positive (POS) or negative 
(NEG) electrospray ionization (ESI) mode. Metabolites were separated using C18-RP 
(ACQUITY UPLC BEH C18 1.7 uM, Waters) chromatography at a flow rate of 
0.3mL/min. The solvent system was A= 20mM ammonium acetate + 15mM NH3 in 
water, and B=acetonitrile:water (95:5). The linear gradient elution started at 100% A 
(time 0-2 min), 65% A (time 2-5 min) and finished at 100% B (time 5.5 min). MRM 
transitions were: GSH (NEG, 306 à 143.2, 128), GSSG (NEG, 611.1à 306.2, 143), 
ATP (POS, 508à 136, 410), ADP (POS 428 à 136, 348). Cellular ATP content was 
determined using a luminescence assay (ThermoFisher) according to manufacturer’s 
instructions and the relative ATP levels were normalized by the protein content of 
each sample.  
Seahorse bioanalyzer analysis 
Cellular respiration was measured using a Seahorse XF24 bioanalyzer (Seahorse 
Biosciences). U2OS or MDA-MB-231 cells were seeded at 50,000-75,000 cells/well 
respectively on XF24 V7 PS cell culture microplates (Seahorse Biosciences, 100777-
004) and cultured for 16 h prior to the analysis. The analysis was performed 
according to the manufacturer’s instructions in DMEM (Seahorse Bioscience 102353-
100) supplemented with 5.5mM D-glucose and 2mM L-glutamine for the OCR 
experiments. For OCR measurement (Mito Stress Test), the following reagents were 
added: oligomycin (1μM), FCCP (0.4μM), and rotenone (1μM) + antimycin A (1μM). 
For the ECAR analysis (Glycolysis Stress Test) the following reagents were added: 
glucose (10mM), oligomycin (1μm) and 2-DG (50mM). For the OCR analysis of 
individual complexes, digitonin (25μg/mL) was added to the media to allow cells to 
permeabilize for approximately one hour, followed by sequential injections of malate 
(2.5mM) + pyruvate (5mM), rotenone (1μM), succinate (10mM) and antimycin (5μM). 
Results were normalized to protein content using the DC Protein assay (Biorad, 500-
0114). 
BioID analysis of proximity interactions 
EXD2 and EXD2-C2 were PCR amplified from previously described clones and 
dExd2 (CG6744) was amplified from sequence verified cDNA clones purchased from 
Gene Synthesis (Life Technologies) with primers containing 5’ AscI or 3’ NotI 
restriction sites (see Supplementary Table 3 for primers) using KOD Hot Start DNA 
Polymerase (Millipore) and cycling conditions recommended from the manufacturer 
(Polymerase activation at 95°C for 2 min, denaturation at 95°C for 20 sec, annealing 
at 55°C for 10 sec and extension at 70°C for 50 sec, repeated for 40 cycles). PCR 
products were purified using the PureLink Quick Gel Extraction Kit (Invitrogen) and 
cloned into pCR2.1-TOPO vector (Invitrogen). Top10 competent E. coli cells 
(Invitrogen) were transformed with pCR2.1-TOPO clones and colonies were selected 
in carbenicillin. Constructs were verified by restriction digestion and sequencing 
(Macrogen) with primers for the TOPO vector (T7 Promoter-F and M13-R). 
Afterwards, EXD2, EXD2-C2 and dExd2 were cut from the pCR2.1-TOPO vector by 
restriction digestion with AscI (NEB) and NotI-HF (NEB), purified using the PureLink 
Quick Gel Extraction Kit (Invitrogen) and ligated into pcDNA5/FRT/TO-C-FLAG-
hBirA* (kind gift from Dr. Brian Raught) using Quick Ligation Kit (BioLabs). Top10 
competent E. coli cells (Invitrogen) were transformed and carbenicillin selected and 
the constructs were confirmed by restriction digestion and sequencing (Macrogen). 
For expression in Drosophila Schneider 2 (S2) cells, dEXD2-BirA*-FLAG was PCR 
amplified and subcloned into the pMK33-C-TAP-FLAG-HA-BD plasmid backbone 
(Flybase: FBmc0003027).  
AD293 cells were seeded and transfected the next day with BirA* vectors using PEI 
(Polysciences Euro GMBH) +/- 50μM biotin (IBIAN Biotechnology 2-1016-002). For 
mass spectrometry, 5x15cm plates per condition were harvested 24h post-
transfection by trypsinization, washing 2X in PBS and snap freezing on dry ice. Cell 
pellets were lysed in 5ml modified RIPA buffer (150mM Tris-HCl pH 7.5, 150mM 
NaCl, 1mM EDTA, 1mM EGTA, 1% Triton X-100, 0.1% SDS, 1:500 protease inhibitor 
cocktail (Sigma-Aldrich), 1:1000 benzonase (Novagen)) on ice and biotinylated 
proteins were isolated using streptavidin-sepharose beads (GE). Proteins were 
washed in Ammonium bicarbonate and digested with trypsin. Mass spectrometry was 
performed as previously described51. 
Sucrose gradient analysis of mitochondrial ribosomes 
U2OS cells were treated with 100μg/ml CAP and incubated at 37°C for 10 min. Cells 
were then washed and homogenized in ice-cold STE buffer (250mM sucrose, 5mM 
TrisHCl pH 7.5 and 1mM EGTA, 2mM DTT, 100μg/ml CAP, 20U/ml RNase inhibitors 
and 1X complete protease inhibitor) with a glass Dounce homogenizer (40 tight 
strokes). Mitochondria were obtained by differential centrifugation and loaded 
(0.9mg) on a 5ml linear sucrose gradient (10-30% [vol/vol]) in a gradient forming 
buffer (20mM Tris-HCl pH 7.5, 10mM MgCl2, 100mM KCl, 2mM DTT, 100μg/ml 
chloramphenicol, 20U/ml RNase inhibitors and 1X complete protease inhibitor). The 
gradients were centrifuged for 2 h at 39,000rpm at 4°C and fractions of 350μl were 
collected from the top and precipitated with TCA. Samples were then analyzed by 
SDS-PAGE and qRT-PCR. 
Analysis of mitochondrial translation 
To analyze the rate of mitochondrial translation, experiments were performed 
essentially as described21 with minor modifications. 400,000 cells were plated on 6 
cm plates the day prior to the experiment. Media was replaced with 2ml DMEM 
lacking methionine or cysteine (Life Technologies) with 10% dialyzed FBS (Hyclone) 
for 20 min. 100μl of 6 mg/ml sterile filtered emetine (Sigma) in PBS was added to the 
media for 10 min followed by the addition of 200μCi/ml of 35S EasyTag (Perkin Elmer) 
for 1 h. For some experiments, CAP (Sigma) was added at 40 μg/ml to inhibit 
mitochondrial translation or the anti-oxidant NAC (Sigma) was added at 5 mM. 
Labeling media was removed and cells washed 2X in PBS followed by a 10 min 
incubation in DMEM with 10% FBS and P/S. Cells were washed 3X in PBS and 
scraped into 1ml PBS. Following gentle centrifugation at 1,000g, cell pellets were 
resuspended in RIPA buffer (50mM Tris–HCl pH 7.5, 150mM NaCl, 1% NP-40, 1mM 
MgCl2, 1X EDTA-free protease inhibitor cocktail (Roche)), nuclei pelleted by 
centrifugation at 2,000xg for 10 min and the protein concentration determined by a 
modified BCA assay (Biorad). 20-40μg of lysate was run on a 14% SDS-PAGE gel 
and transferred to PVDF membrane by western blotting. Dried membranes were 
exposed to a Storage Phosphor Screen (Molecular Dynamics) for 3 to 8 days and 
imaged using a Typhoon 8600 Variable Mode Imager (Molecular Dynamics). 
Contrast was adjusted and band intensity was quantified using ImageJ49. In organello 
Drosophila translation assays were performed as previously described27. Briefly, 
mitochondria were isolated from third-instar larvae and treated with 200μg/ml 
emetine and 100μg/ml cyclohexamide to inhibit cytoplasmic translation. 0.4mg of 
isolated mitochondria were incubated with 178 μCi 35S EasyTag (Perkin Elmer) for 1 
h at 30°C and equal amounts of mitochondrial protein were loaded on a 14% SDS-
PAGE gel and transferred to PVDF membrane by western blotting at 100V for 1 h. 
Labeled proteins were visualized by autoradiography as previously described. 
Protein purification and enzymatic assays  
Recombinant EXD2 (61-621) was used for protein expression due to its improved 
solubility and yield. It was PCR amplified and cloned into pet28a with an N-terminal 
His-SUMO tag using BsmBI and XbaI and protein was expressed in E.coli 
Bl21(DE3)pLysSRARE by the addition of 1mM IPTG at 25°C for 3 h. Soluble proteins 
were purified using Nickel affinity resin in 50mM Tris Ph7.5, 500mM NaCl, 10% 
glycerol and eluted with increasing imidazole concentrations (up to 300mM). The 
resulting protein was then further purified by gel filtration using a Superdex 200 
10/300 GL column (GE Healthcare) in 50mM Tris pH 7.5, 500mM NaCl, 10% glycerol. 
To confirm the activity was that of EXD2 rather than potential contaminants, 
mutations D108A and E110A (EXD2-NUC) were generated in the active site by site-
directed mutagenesis. In addition, an EXD2-C1/2 mutant was generated (420CxxC to 
SxxS and 460CxxC to SxxS) using a QuikChange Lightning Site-Directed 
Mutagenesis Kit (Agilent Technologies, 210518-5). These proteins were then 
expressed and purified as described for the WT.  
WRN exo (1-333) was purified as described previously52. Briefly, the protein was 
expressed in E.coli Bl21(DE3)pLysSRARE by the addition of 1mM IPTG at 25°C for 4 
h. Protein was purified on nickel affinity resin in 50mM Tris Ph7.5, 500mM Nacl, 10% 
glycerol, Q ion exchange chromatography in 50mM Tris Ph7.5, 10% glycerol followed 
by gel filtration using an S200 column in 50mM Tris Ph7.5, 500mM Nacl, 10% 
glycerol. 
For enzymatic activity assays, 5-80nM protein was incubated with 20nM 5’ FAM or 
Cy5 labeled DNA/RNA in 50mM Tris pH7.5, 0.5μg/ml BSA and 10% glycerol with the 
addition of 10nM MnCl2 or MgCl2. Reactions were incubated at 37°C for 30 min 
before DNA was denatured by boiling in 35% formamide. Where substrates 
contained RNA, 50% formamide was added and no boiling step was used. DNA was 
separated on an 18% polyacrylamide urea TBE gel (21W, 2 h) and products were 
visualized using a Fujifilm FLA-5100 image reader. For the blocked 5’ end oligo 
assay, 0.5 units ExoI (NEB) was used as a positive control and the reaction was 
carried out in the supplied reaction buffer. Oligos were annealed to form double 
stranded (ds) substrates in 10mM Tris pH 7.5 by boiling followed by slow cooling.  
Electrophoretic mobility shift assays (EMSA) 
For electrophoretic mobility shift assays (EMSA), 20-310nM protein was incubated 
with 20nM 5’ FAM or Cy5 labelled DNA/RNA in 50mM Tris pH 7.5, 0.5μg/ml BSA and 
10% glycerol and incubated on ice for 30 min. Complexes were then separated on an 
8% polyacrylamide gel in 0.5x TBE (75V for 80 min) and products were visualized 
using a Fujifilm FLA-5100 image reader. All primers used are listed in Supplementary 
Table 3. 
Drosophila stocks and maintenance 
Drosophila melanogaster with a transposon insertion mapped to CG6744/dExd2 
(y1 w67c23; P{EPgy2}CG6744EY03872; stock #16578) were obtained from the 
Bloomington Drosophila Stock Center at Indiana University 
(http://flystocks.bio.indiana.edu/) and reduced transcript level was confirmed by qRT-
PCR as described. Flies were maintained at 25 °C on a 12 h:12 h light:dark cycle at 
constant humidity. Flies were back-crossed to our control yellow white flies for 8 
generations prior to performing the analyses reported here. 
Drosophila food preparation 
For lifespan analysis, different fly-food formulations were prepared. Normal food 
(100g yeast, 100g sugar, 20g agar, 30ml nipagen and 3ml propionic acid per liter of 
food); Low Sugar food (100g yeast, 50g sugar, 20g agar, 30ml nipagen and 3ml 
propionic acid per liter of food); Low Yeast food (50g yeast, 100g sugar, 20g agar, 
30ml nipagen and 3ml propionic acid per liter of food); Antioxidant food (100g yeast, 
100g sugar, 20g agar, 30ml nipagen, 3ml propionic acid and 10mg/ml NAC per liter 
of food); and Paraquat (PQT) food (100g yeast, 100g sugar, 20g agar, 30ml nipagen, 
3ml propionic acid and 5mM PQT). To prepare each diet, yeast, sucrose and agar 
were first dissolved in water and boiled for 10 min. After cooling, propionic acid and 
nipagen were added, and the food was distributed into the glass vials and allowed to 
solidify. Finally, NAC or PQT were added to the specific diets. 
Analysis of Drosophila lifespan, fecundity and development  
To assess lifespan, newly hatched flies from each genotype were allowed to mate for 
48 h, after which females and males were separated and grouped into 30 flies per 
vial. Food vials were changed every 3 days and deaths were scored until all flies 
were dead. To determine fecundity, age- and diet-specific flies from each genotype 
were allowed to mate for 4 h and fecundity was estimated from 6 independent egg-
counts. The mean number eggs/fly was calculated. For the analysis of development, 
0-4 h embryos were collected on grape-juice agar plates. To assess pupariation, 40 
newly hatched larvae were transferred to specific-food vials. Once the L3 stage was 
reached, larvae were monitored and new pupae were counted every 2 h. For size 
measurements, 0-4 hours embryos and pupae were mounted for imaging and 
processed with ImageJ49. Expression data shown in Supplementary Fig. 6c was 
obtained from ModENCODE/FlyBase53, 54 
Culture and transfection of Drosophila S2 cells  
Drosophila Schneider 2 cells (S2) were maintained at 25ºC in Schneider’s Drosophila 
medium (Lonza) supplemented with 10% (v/v) FBS (Gibco, 10270-500ML) and 
50μg/ml P/S (Gibco, 15140-122). S2 cells were transfected using Effectene (Qiagen, 
301425) following the manufacturer’s protocol.  
Oxygen consumption measurement 
Oxygen consumption was measured in inverted and permeabilized larval tissues 
using an Oxygraph-2k (Oroboros) as previously described55. Mitochondrial-
dependent respiration was measured by supplying ETC substrates: 10mM glutamate, 
2mM malate, 2.5mM ADP and 10mM succinate. Larvae were then stressed with 
0.5μM of FCCP to measure maximal respiration and the ETC was inhibited by adding 
0.5μM rotenone and 2.5μM antimycin. Final values were normalized to the protein 
content of each sample. 
Transmission electron microscopy (TEM) 
HEK293T-cells stably overexpressing EXD2-WT-SF or empty control SF-vector 
(Cont-SF) were grown to 80% confluency, washed 3X in PBS and fixed in 2.5% 
glutaraldehyde for 1 h. Cells were detached by scraping and pelleted (4°C, 2,500rpm 
for 10 min). Pellets were washed in 0.1M PB 4X for 10 min, stained with 1% OsO4 for 
1 h and washed again for 10 min in 0.1M PB. Cells were dehydrated at 4°C (series of 
acetone concentrations: 50, 70, 90, 96, 100%) prior to embedding. Sections were cut 
with a UCT ultramicrotome (Leica Microsystems) and incubated with blocking buffer 
(5% and 1% BSA) in 0.01M PBS solutions for 10 and 1 min, respectively). Grids were 
incubated 30 min at RT with polyclonal FLAG antibody (Sigma) diluted 1 to 10 in 
blocking buffer (1% BSA in 0.01M PBS). After four washes (0.25% Tween 20 in 
0.01M PBS for 4 min and 1% BSA in 0.01M PBS for 1 min), sections were incubated 
with IgM anti-rabbit coupled colloidal gold particles (Jackson, West Grove, USA) 
diluted in blocking buffer for 15 min, rinsed with water, rinsed in 0.01M PBS, fixed in 
1% GA in 0.01M PBS, and rinsed abundantly in ddH2O. Sections were stained with 
1% potassium permanganate and 1% UA in water for 15 min. Controls for non-
specific binding of the colloidal gold-conjugated antibody were performed by omitting 
the primary antibody. Electron micrographs were obtained with a Jeol JEM 1010 MT 
electron microscope (Japan) operating at 80kV in the Electron Microscopy core unit 
of the Parc Cientific de Barcelona.  
Alamar Blue survival assays 
Measurements were made according to manufacturer´s instructions (Invitrogen, 
DAL1025). Briefly, cells were seeded at a density of 300 cells per well in 96-well 
plates and allowed to attach overnight. After completion of drug treatments (7 days), 
a dilution 1:10 of Alamar Blue reagent in medium was added to each well. After 2-4 h 
incubation at 37ºC, fluorescence was measured in a FL600 Microplate Fluorescence 
Reader (BIOTEK). 
Colony formation assays 
For colony formation assays, cells were seeded at a density of 300 cells per well in 
6-well plates and allowed to attach overnight. After completion of drug treatments (12 
days), cells were stained with 0.1% crystal violet in 20% methanol. The number of 
colonies was analyzed using ImageJ49. Cells were treated with the indicated doses of 
CPT-11 (Sigma, I1406), mitomycin-C (MMC; Sigma, M4287) or Olaparib 
(Selleckchem, AZD2281). 
Blue Native Page electrophoresis 
Blue native PAGE (BN-PAGE) analysis was performed according to a previously 
published protocol56. Briefly, 200μg of mitochondria were isolated from U2OS cells, 
solubilized with 8g/g digitonin and loaded into a gradient gel. Coomassie staining 
allowed for the identification of mitochondrial complexes.  
MitoString assay 
Total RNA was isolated according to manufacturers instructions (PureLink RNA mini 
kit, Ambion). The MitoString assay was performed as described28.  
2D-agarose gel electrophoresis  of mitochondrial replication intermediates 
2D agarose gel electrophoresis (2D-AGE) was carried out as described previously57. 
Briefly, total DNA was extracted from 4x106 cells using Phenol chloroform and 
proteinase K. 30µg total DNA was digested with HinCII (NEB) and DNA was then 
separated in the first dimension on a 0.4% TBE agarose gel without ethidium 
bromide (EtBr) for 18 h at 1.1 V/cm. The lane was then cut from the gel and rotated 
90° and the DNA was further separated in a 1 % TBE agarose gel containing 500 
ng/ml EtBr for 6 h at 260 mA, 4°C. The gel was Southern blotted and DNA was 
identified using a radioactive probe made using Ready-To-Go™ dCTP DNA labeling 
beads (GE healthcare). The probe was specific to region 16341-151 and was 
generated by PCR (primer sequences in Supplementary Table 3)58. Labeled 
membranes were exposed to a phosphor screen that was scanned using a Fujifilm 
FLA-5100 image reader. 
Computational and phylogenetic analysis 
Human EXD2 was used as a query in phmmer searches (20718988) in a database of 
reference proteomes focusing on the UNIPROT reference proteomes having 
complete genomes. We extracted the EXO domain multiple sequence alignment from 
the PFAM database (PFAM name is DNA_pol_A_exo1), built a hidden Markov profile 
from the seed alignment using HMMER(http://hmmer.org/) and searched in our 
database of Reference proteomes with this profile. Then we collected all the 
sequences having and EXO domain (~300 sequences). The HNH domain was 
extracted from PFAM (PFAM name HNH) and we built a hidden Markov profile for 
searching our database. EXD2_HUMAN was recovered at a significant e-value 
above threshold. We next scanned all of the sequences for additional domains using 
hmmscan  (from HMMER suite) to annotate the sequences. Multiple sequence 
alignments of proteins were conducted using MAFFT in its slow and accurate version 
(L-IN-SI)59. Alignments were visualized in Belvu60 and Jalview61.  Sequence 
alignments shown in Supplementary Fig. 1a, c-e performed using the T-Coffee 
webserver62, the output formatted in Jalview61 and modified in Adobe Illustrator. 
Mitochondrial targeting probability was predicted using MitoProt II62. 
For the phylogenetic analysis, we conducted two different phylogenies, using only the 
EXO domain; a large tree of ~290 sequences, including a large number of bacterial 
sequences (available upon request), and a refined tree including representative 
sequences exhibiting different domain arrangements (Supplementary Fig 1b). We 
conducted probabilistic-based phylogenies using MrBayes63. A total of 4 independent 
chains with 4 runs were run under a mixed model of evolution over 5 million 
generations. 25% percent of initial trees were discarded and a total of 1,500,004 
trees were sampled. Specific parameters to run the search were: prset 
aamodelpr=mixed; lset rates=gamma; relburnin=yes burningfrac=0.5. The tree was 
annotated using in-house scripts to show the domain distributions associated with the 
EXO domains in these sequences and visualized using iTOL64. Additional analyses 
were run using alternative ML–base methods, in particular RAxML, giving the same 
topologies.  
For the structural bioinformatics analysis of the EXD2 HNH domain (aa 408-470), 
The EXD2 HNH-like domain was modeled using SCWRL65 and superimposed on the 
PDB structures with the best Fold and Function Assignment (FFAS03)66 scores 
(5X42: Legionella pneumophila DotN: score -15, 5H0M: deep-sea thermophilic 
bacteriophage GVE2 HNH endonuclease67: score -12.0, 5MKW: Human ZRANB3 
HNH domain68: score -11.7 and 1OGY: heterodimeric nitrate reductase NAPB from 
Rhodobacter sphaeroides69: score -11.1). Several structures were obtained as 
reliable templates (between -9 and -16) and the best scoring template in terms of 
alignment length, %identity and %of gaps (5H0M) was used to generate the model in 
Supplementary Fig. 1d. 
Statistics and reproducibility 
Statistical analysis was performed using Prism 7 and R. An unpaired two-tailed t-test 
was performed when comparing two groups except when stated otherwise. An 
ANOVA test was used when comparing more than two groups, followed by Dunnett’s 
multiple comparison test. For metabolomics data, raw data was median-centered, 
and metabolite levels compared between shCont and shEXD2-22 groups using a 
two-tailed t-test. False discovery rate was controlled using the Benjamini & Hochberg 
procedure (p-adjusted < 0.1 and FC above 1.3 in absolute value was used for 
statistical significance). Data analysis was performed using R version 3.2.0. MetPa70 
was used to perform pathway enrichment and topological analysis. Survival or 
cumulative hazard functions were estimated using the Turnbull method for interval 
censored data using Kaplan-Meier estimates as a baseline and comparisons 
performed by proportional-hazard Cox models with interval censored data 
implemented in Rpackage (https://cran.r-
project.org/web/packages/icenReg/index.html). GSC attrition was analyzed with a 
proportional odds cumulative link model (ordinal regression) implemented in 
Rpackage (https://cran.r-project.org/web/packages/ordinal/index.html). P-values were 
adjusted for multiple testing using the Benjimini and Hochberg method and Hazard 
Ratios (HR) and their corresponding 95% confidence intervals were computed as a 
measure of association for data in Fig. 7i, 8a and 8e. Experiments were generally 
performed 2-3 times except for Supplementary figure 1f, 1h-j and 4a, which were 
performed once. 
Data availability 
Metabolomics data and statistics used for Figs. 2c and 2f are provided in 
Supplementary Table 1. Raw data for Fig. 2 is available in the Metabolights 
repository (ID: MTBLS247 (http://www.ebi.ac.uk/metabolights/MTBLS247)) and an 
annotated summary of BioID-MS data from Fig. 4 is provided in Supplementary Table 
2 and raw data available in the MassIVE repository (ID: MSV000081337). Additional 
source data and statistical information for all plotted figures is provided in 
Supplementary Table 1 and uncropped blots and gels in Supplementary Figure 9. All 
other data are available from the corresponding author upon reasonable request.  	
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EXD2 governs germ stem cell homeostasis and lifespan by promoting 
mitoribosome integrity and translation 
 
Supplementary Legends 
 
Supplementary Figure 1: EXD2 is a conserved mitochondrial exonuclease with 
an HNH-like domain. (a) Pairwise sequence alignments of 3’-5’ exonuclease 
domains of human EXD2 (aa 89-261) and WRN (aa 60-228). 3 conserved 
exonuclease signature motifs of DNAQ family highlighted in light blue boxes and 
metal binding residues indicated with asterisks. Nuclease dead mutations (EXD2-
NUC) shown in red. (b) Unrooted Bayesian phylogenetic tree based on multiple 
sequence alignment of the EXO domain (PFAM: DNA_pol_A_exo1) from 44 
representative sequences (domain codes indicated in key at top). Red balls indicate 
probability support for clades when they are >0.9%. Eukaryotic phyla indicated by 
text color: animals (blue), plants (dark green), algae (light green) and fungi (pink). 
Protein domain architectures annotated with hmmscan and hidden Markov models 
(see methods) for each protein. (c) Multiple sequence alignment of HNH-like 
domains (human aa 411-469) of representative EXD2 sequences. The HNH-like 
domain mutations in the EXD2-C1 or C2 alleles indicated in red. (d) Alignment of 
human EXD2 with HNH domains in non-EXD2 proteins. Superimposition of modeled 
EXD2 HNH-like domain with 5H0M: deep-sea thermophilic bacteriophage GVE2 
HNH endonuclease. EXD2 in cyan and the Cys residues of the CxxC dyads in red 
coordinating a zinc ion. Catalytic DH residues characteristic of HNH endonuclease 
activity are not present in EXD2 (red box). (e) Alignment of EXD2 mitochondrial 
targeting sequences (MTS) from indicated species with hydrophobicity and predicted 
mitochondrial targeting probability. (f) Overexpressed EXD2-SF imaged by TEM in 
HEK293 cells using gold nano-particles conjugated to anti-rabbit antibodies to 
	 2	
recognize the FLAG antibody. Particles in the nucleus (blue), cytoplasm (black) and 
mitochondria (red) indicated by arrows. 1 experiment was performed. Semi-
quantitative analysis of localization normalized by area is graphed (65 and 49 fields 
per condition, respectively) and percentage of particles graphed. (g) Relative 
localization of EXD2 in the cytoplasm or mitochondria. Percentage of particles in the 
mitochondria or cytoplasm in 25 fields graphed and example image shown (2 
experiments). Scale bar=1μM. (h) EXD2 is mitochondrial and resistant to 25µM 
FCCP treatment relative to outer membrane TOM20. U2OS cells were treated with 
FCCP for indicated time and fractionated (C=cytoplasm, M=mitochondria, N=nucleus, 
Ch=chromatin) for western blotting for GAPDH (cytoplasm), OXPHOS components 
ATP5A, URQC2, CO1 and SDHB (inner membrane/matrix), TOM20 (outer 
membrane) and EXD2. The experiment was performed once. 
 
Supplementary Figure 2: Cellular phenotypes of EXD2 deficient cells. (a) EXD2 
–deficient MDA-MB-231 and U2OS cells generated by CRISPR/CAS9 targeting and 
complemented with wild type (WT) EXD2 or indicated mutants. One representative 
western blot out of 3 of EXD2 and GAPDH (loading control) is shown. (b) Liquid 
chromatography-mass spectrometry (LC-MS) analysis of glutathione (GSH/GSSG) 
with parallel samples treated with NAC. Color key of cell line or treatment with CAP 
or FCCP applies to all of figure. Averages of n=3 (WT, EXD2-KO1, EXD2-KO1+WT 
w/ NAC) or n=4 (all other samples) independent cultures shown with mean(SD). (c) 
MtDNA levels of indicated cell lines with indicated stable shRNAs. Mean (SD) of n=3 
independent experiments. (d) MtDNA levels of indicated MDA-MB-231 cells. Parallel 
cultures were treated with NAC to reduce ROS levels. Mean (SD) of n=3 independent 
experiments *p<0.05, **p<0.01, ***p<0.0001 one way ANOVA with Dunnet’s test for 
(c) and (d). (e) Mitochondrial mass measured with MitoTracker Green FM or 
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MitoTracker Deep Red staining. Parallel samples were treated with FCCP. Untreated 
MitoTracker Green samples also shown in Fig. 3d. Mean(SD) of n=3 independent 
experiments. (f) 2D-AGE analysis of mitochondrial replication intermediates in U2OS 
or HEK293T cells stably expressing shCont or shEXD2-22. Schematic of replication 
intermediates (top right panel) and location of probe and restriction sites (bottom right 
panel) shown. 2 experiments are shown. (g) Reduced colony formation of cells with 
stable shRNA against EXD2 in glutamine free media relative to cells in DMEM with 
glucose and glutamine. Mean (SD) of n=3 independent experiments. **p=0.0014 and 
*p=0.0202, unpaired t-test, two tailed. (h) OCR (mitochondrial stress test: Oligomycin, 
FCCP and Antimycin and Rotenone) and (i) ECAR (glycolysis stress test: Glucose, 
Oligomycin and 2-DG) in MDA-MB-231 cells. All time course values of 1 experiment 
with quadruplicate cultures per genotype plotted with mean. (j) OCR measurements 
from 5mM NAC treated MDA-MB-231 cells. Mean and individual values from 1 
experiment with quadruplicate cultures. (k) ATP levels measured in MDA-MB-231 
cells treated with 5mM NAC (as in Fig. 3n). Values from n=3 independent duplicate 
cultures shown with mean(SD). (l) ATP levels measured in U2OS cells by targeted 
mass spectrometry. Results of 8 (WT, EXD2-KO1) or 9 (EXD2-KO1+WT) 
independent cultures shown with mean(SD) (p=0.0155*, unpaired t-test, two tailed).  
 
Supplementary Figure 3: Protein interactions, OXPHOS complexes and 
respiration. (a) EXD2 pulls down NDUFA9 but not ND6 in immunoprecipitation-
western blotting of U2OS cell extracts. (b) Separation of digitonin-solubilized 
mitochondrial complexes in BlueNative-PAGE (BNP) gels; oxoglutarate 
dehydrogenase complex (O), pyruvate dehydrogenase (P) supercomplex I+III 
(CI/CIII), complexes I, V and IV (CI, CV and CIV), non-specific band (NS). Individual 
results from n=3 independent experiments are shown. Western blotting of one gel 
	 4	
(right panel) shows equal loading and that EXD2 is not likely present in the fully 
assembled Complex I. (c) Quantification of reduced OXPHOS complex levels in 
EXD2 deficient cells (n=3, see (b)). The relative band intensity of the EXD2-KO1 
sample compared to WT (set to 1.0) was normalized to the background (*p=0.473 
(CI/CIII), ***p=.0002 (CI) and *p=0.37 (CV), t-test, two tailed). Values with mean(SD) 
are shown. (d) Complex I activity is reduced in cells lacking EXD2. Analysis of OCR 
to assess the activity of individual OXPHOS complexes by consecutive 
administration of malate and pyruvate (Complex I substrate), rotenone, succinate 
(Complex II substrate) and antimycin. The impairment in OCR was more apparent for 
Complex I activity, as Complex II was relatively unaffected. Individual measurements 
from n=2 independent experiments in quadruplicate are shown with mean.  
 
Supplementary Figure 4: Mitoribosome fractionation and translation.  (a) 
Sucrose gradient fractionation followed by 600 U/ml RNAseA treatment for 30 
minutes. Note that profiles are similar regardless of EXD2 and aberrant fractions are 
lost, indicating RNA dependence. The experiment was performed once. (b) 
Examples of 7 independent experiments used in the quantification of COX3/2 
translation (Fig. 5d) or shown as representative in Fig. 5c. Membranes from 2 
independent experiments performed in duplicate are shown. Color key applies to all 
panels. (c) Membranes from 2 independent experiments in addition to those shown 
in Fig. 5c and 5d. (d) Technical replicate of the experiment in Fig. 5f (top panel) and 
independent experiment in duplicate (bottom panel). (e) 2 independent translation 
experiments in RPE1 cells and quantification of the translation defect from n=3 
independent experiments with mean(SD) (**p=0.0025, unpaired t-test two tailed). 
Western blotting for EXD2 and GAPDH as a loading control are shown. Source data 
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and statistical information are shown in Supplementary Table 1 and uncropped blots 
in Supplementary Fig. 9. 
 
Supplementary Figure 5: Protein purification, biochemical analysis and mtRNA 
processing. (a) Coomassie stained gel with protein eluted from an S200 gel filtration 
column shown for all proteins used. Red arrow highlights fractions used.(b) EXD2 
has a 3’-5’ polarity. 20nM of the indicated protein or 0.5U of ExoI were incubated with 
20nM ssDNA with 3’ TAMRA, no modification or 3’ phosphate in the presence of 
10mM MnCl2. Black arrowhead;30 bp. (c) EXD2-WT or WRN-Exo (10-40nM) were 
incubated with 20nM fluorescently labelled dsDNA with a nick, a 1 nt gap, a recessed 
3’ end or the labelled ssDNA oligo alone in the presence of MnCl2. Black 
arrowhead ;16 bp. (d) WRN-Exo (5-80nM) was incubated with  fluorescently labelled 
ssDNA or dsDNA or (e) 20nM fluorescently labelled ssRNA or RNA/DNA hybrid in 
the presence of MnCl2. Bold font;labelled molecule. Sepia panel;same gel scanned 
with a second laser to visualize the Cy5 labeled DNA strand. (f) WRN-Exo (5-80nM) 
and EXD2-C1/2 (5-80nM) were incubated with a dsRNA substrate labelled with FAM 
(forward) or Cy5 (reverse) in the presence of  MnCl2. Sepia panel; same gel scanned 
with a second laser to visualize the Cy5 labeled DNA strand. (g) EXD2-C1/2 (5-
80nM) was incubated with  fluorescently labelled ssDNA or dsDNA in the presence of 
MnCl2. (h) WRN-Exo (5-80nM) was incubated with fluorescently labelled ssDNA or 
dsDNA or (i) 20nM fluorescently labelled ssRNA or RNA/DNA hybrid in the presence 
of MgCl2. Bold font ;labelled molecule. (j) WRN-Exo (5-80nM) and EXD2-C1/2 (5-
80nM) were incubated with a dsRNA substrate labelled with FAM (forward) or Cy5 
(reverse) in the presence of MgCl2. (k) EXD2-C1/2 (5-80nM) was incubated with 
fluorescently labelled ssDNA or dsDNA in the presence of MgCl2. All reactions in 
panels b-k were carried out for 30 min at 37°C before being separated on an 18% 
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polyacrylamide urea TBE gel. Black arrowhead; 30 bp (d-k). (l) Specific activity (nM 
substrate cleavage/nM protein per minute) of the indicated protein measured from 
scanned gels.. Duplicate measurements from n=3  experiments (EXD2-WT and 
WRN-Exo) or n=2 experiments (EXD2-C1/2) are plotted with mean indicated. (m) 
WRN-Exo (80-310nM) was incubated with fluorescently labelled ssDNA or ssRNA, 
RNA/DNA hybrid or dsDNA for 30 min on ice. Complexes were separated on a 0.5x 
TBE 8% polyacrylamide gel. ,Data in b-e, g-i, and k: representative of 3 experiments; 
Data in f, j, m, f: representative of 2 experiments. Source data in Supplementary 
Table 1 and uncropped gels in Supplementary Fig. 9. 
 
Supplementary Figure 6: EXD2 is conserved in Drosophila melanogaster. (a) 
Protein sequence alignment of human EXD2 and dEXD2 (CG6744). MTS is shaded 
in yellow, nuclease domains in blue and HNH-like domain in green for reference. (b) 
QRT-PCR analysis for dEXD2 at the indicated developmental stages of D. 
melanogaster.  Individual values from n=2 experiments with mean indicated. (c) 
Heatmap of ModENCODE/FlyBase dExd2 expression data in Reads Per Kilobase of 
transcript per Million mapped reads (RPKM) during different developmental stages. 
L1-L3 = larval stages 1-3 and WPP = white prepupae. Data represent one out of 2 
experiments. (d) Analysis of maternal contribution to larvae size. Heterozygous 
dExd2 mutant females were bred with homozygous males so that all progeny receive 
functional mitochondria from dExd2 heterozygous mothers. Roughly 50% of the 
progeny (green) are runted to a similar extent as those from breedings with 
homozygous parents (blue), indicating that growth defects are not strictly due to 
maternal inheritance of defective mitochondria. Flies were genotyped by eye color 
(example pictures shown on right) and the size distribution of larvae from Control flies 
or breedings of homozygous mutants are shown for reference. Volumes of n=50 flies 
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per genotype are shown with mean(SD). (e) Schematic model of the proposed role of 
EXD2 in facilitating mitochondrial translation and homeostasis, see main text for 
details. 
 
Supplementary Figure 7: MitoString, subcellular fractionation, influence of 
EXD2 on DNA damage responses and lifespan. (a) Location of MitoString1 probes. 
rRNAs, mRNAs and tRNAs encoded by the mtDNA are labeled in black text (tRNAs 
annotated by their one letter symbols). Location of mRNA probes noted in red, 
junction probes in blue and non-coding probes in green. Rectangles indicate probes 
targeting the heavy strand, while triangles indicate probes targeting the light strand. 
(b) Graphical depiction of the relative change of each of the MitoString probes 
compared to WT. Individual normalized values from quadruplicate samples shown as 
a box and whiskers plot. The box represents the interquartile range and the whiskers 
the minimum to maximum value. All 4 individual values are plotted as circles. (c) 
Subcellular fractionation using previously reported2 methods in the presence or 
absence of DNA damage induced by 1μM CPT. Representative image of 2 
experiments is shown. (d) Examples of U2OS cells immunostained for RPA2 (green) 
with and without 1μM CPT treatment. DNA is stained with DAPI (blue). (e) 
Quantification of the RPA2 signal intensity per nucleus. A minimum of 390 cells were 
quantified for each condition and mean is indicated and data represent one out of 2 
experiments. (f-h) Cellular sensitivities of indicated cell lines in either U2OS or MDA-
MB-231 background to the indicated agents determined using Alamar Blue (f,g) or 
colony forming assays (h). For (f,g) n=3 independent experiments plotted with the 
mean(SD) and for (h) n=3 independent experiments with the mean and range 
indicated. 50nM of a small molecule inhibitor for CHK1 (PF477736) was used in 
some experiments as a control to induce DNA damage sensitivity. (i) QRT-PCR 
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analysis of Sir2 mRNA levels between Control and dExd2 deficient flies. Values of 
n=3 independent experiments shown with mean(SD). (j) Calorie restriction (CR) 
using low sugar or low yeast diets extends lifespan regardless of dExd2 status. n=3 
independent experiments with 60 flies for each lifespan condition with the mean(SD) 
indicated with the exception of low yeast where n=2 independent experiments were 
performed and mean is indicated.  
 
Supplementary Figure 8: Flow cytometry gating examples. (a) Examples of 
MitoSox Red (top) and (b) MitoTracker Green FM (bottom) flow cytometry gating 
strategies. More than 10,000 cells were collected per sample and dead cells 
excluded with DAPI staining. Control treatments with 75μM paraquat (PQT) or 25μM 
FCCP were used to induce ROS or reduce mass, respectively. 
Supplementary Figure 9: Uncropped gels and membranes. Uncropped scans of 
membranes and gels used in the main and supplementary figures. 
Supplementary Table 1: Source data and statistical information. Source data 
used for each plot in the paper and accompanying statistical information is provided 
in a separate tab for each figure. 
Supplementary Table 2: Annotated summary of BioID data. Summarized data 
from the BioID experiments used to generate the graph and schematics in Figure 4b 
and 4c. Raw data is available in the MassIVE repository (ID: MSV000081337). 
Supplementary Table 3: Oligonucleotides used in this study. A list of primer 
sequences used in the study. 
Supplementary Table 4: Antibodies. A list of antibodies used in this study and their 
providers. 
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